Abstract
The pharmacokinetic (PK) parameters of lisinopril were obtained in 46 children aged 6 months to 15 years. A lisinopril suspension (0.15 mg/kg per day) was administered to patients <6 years of age; the remaining children received lisinopril tablets, the daily dose being adjusted according to body weight, i.e., 2.5 mg if <25 kg, 5 mg if 25–45 kg, and 10 mg if >45 kg. Blood was drawn predose and on eight occasions postdose in children aged 4–15 years, and on five occasions in those aged <4 years. PK data are reported for the 46 children in terms of age groups: Group I (n = 9), aged 6–23 months; Group II (n = 8), aged 2–5 years; Group III (n = 12), aged 6–11 years; Group IV (n = 17), aged 12–15 years. The dose of lisinopril ranged from 3.07 mg/m2 per day in Group I to 4.78 mg/m2 per day in Group IV. Cmax of lisinopril, which occurred 5–6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC0–24 h ranged from 301–311 ng·h/ml in Groups I and II to 550–570 ng·h/ml in Groups III and IV. No serious adverse events related to lisinopril were reported.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Conroy S, McIntyre J, Choonara I, Stephenson T (2000) Drug trials in children and the way forward. J Clin Pharmacol 49:96–97
Chesney RW, Adamson P, Wells T, Wilson JT, Walson PD (2001) The testing of antihypertensive medications in children: Report of the antihypertensive agent guidelines subcommittee of the pediatric pharmacology research units. Pediatrics 107:558–561
Conroy S, McIntyre J, Choonara I (1999) Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 80:F142–F145
Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Pædiatr 88:965–968
Wells T, Rippley R, Hogg R, Sakarcan A, Blowey D, Walson P, Vogt B, Delucchi A, Lo MW, Hand E, Panebianco D, Shaw W, Shahinfar S (2001) The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol 41:1064–1074
Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, Shahinfar S (2002) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 42:870–880
Gomez HJ, Cirillo VJ, Moncloa F (1987) The clinical pharmacology of lisinopril. J Cardiovasc Pharmacol 9:S27–S35
Schwartz GJ, Haycock GB, Edelman CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263
Thompson KC, Zhao Z, Mazakas JM, Beasley CA, Reed RA, Moser CL (2003) Characterization of an extemporaneous liquid formulation of lisinopril. Am J Health Syst Pharm 60:69–74
Hichens M, Hand EL, Mulcahy WS (1981) Radioimmunoassay for angiotensin converting enzyme inhibitors. Ligand Q 4:43
George SL, Gehan EA (1979) Methods for measurement of body surface area. J Pediatr 94:342–343
Prineas RJ, Elkwire EM (1992) Epidemiology and measurement of high blood pressure in children and adolescents. In: Loggie JMH, ed. Pediatric and adolescent hypertension. Blackwell Scientific Publications, Oxford pp 91–103
Higgins MW, Keller JB, Metzner HL, Moore FE, Ostrander LD Jr (1980) Studies of blood pressure in Tecumseh, Michigan. II Antecedents in childhood of high blood pressure in young adults. Hypertension 2:117–123
Lauer RM, Clarke WR, Beaglehole R (1984) Level, trend, and variability of blood pressure during childhood: the Muscatine study. Circulation 69:242–249
Webber LS, Cresanta JL, Croft JB, Srinivasan SR, Berenson GS (1986) Transitions of cardiovascular risk from adolescence to young adulthood-the Bogalusa Heart Study: II. Alterations in anthropometric blood pressure and serum lipoprotein variables. J Chronic Disord 39:91–103
Luepker RV, Jacobs DR, Prineas RJ, Sinaiko AR (1999) Secular trends of blood pressure and body size in a multi-ethnic adolescent population: 1986 to 1996. J Pediatr 134:668–674
Flynn JT (2000) Neonatal hypertension: diagnosis and management. Pediatr Nephrol 14:332–341
Arar MY, Hogg RJ, Arant BS Jr, Seikaly MG (1994) Etiology of sustained hypertension in children in the southwestern United States. Pediatr Nephrol 8:665–666
National Heart, Lung and Blood Institute (1977) Report of the task force on blood pressure control in children. Pediatrics 59:797–820
National Heart, Lung and Blood Institute (1987) Report of the second task force on blood pressure control in children–1987. Pediatrics 79:1–25
National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents (1996) Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents. A working group report from the National high blood pressure education program. Pediatrics 98:649–658
Sinaiko AR (1994) Treatment of hypertension in children. Pediatr Nephrol 8:603–609
Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, Junggren I-L (1989) Pharmacokinetics of lisinopril (iv/po) in healthy volunteers. Biopharm Drug Dispos 10:397–409
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hogg, R.J., Delucchi, A., Sakihara, G. et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol 22, 695–701 (2007). https://doi.org/10.1007/s00467-006-0399-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-006-0399-5